pharma · Metastatic Solid Tumor · Advanced or Metastatic Solid Tumors · HOWL
Werewolf Therapeutics
Greywolf Therapeutics is a pharma organization headquartered in Milton, GB. It trades on NYSE under ticker HOWL. Primary therapeutic focus areas include Metastatic Solid Tumor, Advanced or Metastatic Solid Tumors. NovaPh
Milton, GB HQ
2017 Founded
53 Employees
Public company Type
HOWL · NYSE Ticker
Company details
- Status
- Public
- HQ
- Milton, GB
- Founded
- 2017
- Employees
- 53
- Programs
- 2
- Drugs
- 0
- Patents
- 10
WTX-330
Phase 2 · small molecule · Advanced or Metastatic Solid Tumors
WTX-330 for Advanced or Metastatic Solid Tumors is a Phase 2 program (small_molecule) at Werewolf Therapeutics with 2 ClinicalTrials.gov record(s).
Internal code WTX-330x2102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Werewolf Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Advanced or Metastatic Solid Tumors
- Status
- active
- Trials
- 2